EMA and FDA have launched on 1 April 2011 a three-year pilot programme to allow parallel evaluation of quality elements, known as Quality by Design (QbD), of selected applications submitted to both agencies at the same time.
FDA and EMA to join forces on quality
Home/Guidelines | Posted 29/04/2011 0 Post your comment
QbD in pharmaceuticals involves an enhanced systematic and science-based approach to development and manufacturing, to better ensure product quality.
Under the programme, both agencies will assess the parts of the applications relevant to QbD, such as development, design space and real-time release testing; separately but with regular communication, leading to a common list of questions for the applicants and a harmonised evaluation of their responses.
In Europe, the pilot programme currently applies only to new marketing authorisation applications and quality-related scientific advice requests. Type II variations may be included on a case-by-case basis. In the US the programme will cover new drug marketing applications, prior approval supplements and chemistry manufacturing control meeting requests. The pilot programme will only include chemical entities. However, who knows—generics may be next.
Participation in the pilot programme is voluntary, and interested applicants/sponsors are asked to notify both agencies three months prior to submission of an application. The pilot programme will conclude on 31 March 2014, when both agencies will jointly assess and publish the outcome of the pilot programme.
Source: EMA
Policies & Legislation
Strategic plans of ANVISA and COFEPRIS to advance health regulation
Panama enacts new bill to guarantees the supply of medicines
Reports
Follow-on biological/biosimilar approvals in Latin America by therapeutic class
Follow-on biological/biosimilar approvals landscape in Latin America
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Global biosimilars guideline development – EGA’s perspective
Related content
New decree for the prescription and commercialization of medicines in Argentina
FDA issues draft guidance on biosimilars and interchangeable biosimilars labelling
WHO’s revised guideline to safe and effective biosimilar products
New FDA guidance on statistical approaches to establishing bioequivalence
Comments (0)
Post your comment